Literature DB >> 703927

Changes in brain cholinesterases in senile dementia of Alzheimer type.

E K Perry, R H Perry, G Blessed, B E Tomlinson.   

Abstract

Acetyl- and butyryl-cholinesterase activities have been measured biochemically in normal brain tissue, in senile dementia of Alzheimer type and in mental disorders without Alzheimer-type abnormalities. Acetylcholinesterase was significantly reduced and butyrylcholinesterase significantly increased, compared with the normal, in the hippocampus and temporal cortex of the Alzheimer cases. No significant enzyme changes were seen in the other diseases investigated including multi-infarct dementia, schizophrenia and depression. There was no correlation between age and acetylcholinesterase activity, but a significant positive correlation between the butyrylcholinesterase activities with increasing age (60-90 years) was found in the hippocampus. The possible connection between cholinergic system pathology and these cholinesterase abnormalities in Alzheimer dementia is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 703927     DOI: 10.1111/j.1365-2990.1978.tb00545.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  109 in total

Review 1.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

2.  Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases.

Authors:  Sultan Darvesh; Ryan Walsh; Earl Martin
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

3.  Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.

Authors:  Ian R Macdonald; G Andrew Reid; E Eric Joy; Ian R Pottie; Gilbert Matte; Steven Burrell; George Mawko; Earl Martin; Sultan Darvesh
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

4.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

Review 5.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

6.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Authors:  Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

7.  Risk of pneumonia in new users of cholinesterase inhibitors for dementia.

Authors:  Edward Chia-Cheng Lai; Monera B Wong; Isao Iwata; Yinghong Zhang; Cheng-Yang Hsieh; Yea-Huei Kao Yang; Soko Setoguchi
Journal:  J Am Geriatr Soc       Date:  2015-04-27       Impact factor: 5.562

8.  Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease.

Authors:  Manuela Bartolini; Nigel H Greig; Qian-Sheng Yu; Vincenza Andrisano
Journal:  J Chromatogr A       Date:  2008-10-04       Impact factor: 4.759

9.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

10.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.